Literature DB >> 31790330

Unpacking Trial Offers and Low Accrual Rates: A Qualitative Analysis of Clinic Visits With Physicians and Patients Potentially Eligible for a Prostate Cancer Clinical Trial.

Lauren M Hamel1, David W Dougherty2, Terrance L Albrecht1, Mark Wojda1, Alice Jordan3, Tanina F Moore1, Nicole Senft4, Michael Carducci3, Elisabeth I Heath1, Mark A Manning1, Louis A Penner1, Seongho Kim1, Susan Eggly1.   

Abstract

PURPOSE: Cancer clinical trial accrual rates are low, and information about contributing factors is needed. We examined video-recorded clinical interactions to identify circumstances under which patients potentially eligible for a trial at a major cancer center were offered a trial.
METHODS: We conducted a qualitative directed content analysis of 62 recorded interactions with physicians (n = 13) and patients with intermediate- or high-risk prostate cancer (n = 43). Patients were screened and potentially eligible for a trial. We observed and coded the interactions in 3 steps: (1) classification of all interactions as explicit offer, offer pending, trial discussed/not offered, or trial not discussed; (2) in interactions with no explicit offer, classification of whether the cancer had progressed; (3) in interactions classified as progression but no trial offered, identification of factors discussed that may explain the lack of an offer.
RESULTS: Of the 62 interactions, 29% were classified as explicit offer, 12% as offer pending, 18% as trial discussed/not offered, and 39% as trial not discussed. Of those with no offer, 57% included information that the cancer had not progressed. In 68% of the remaining interactions with patients whose cancer had progressed but did not receive an offer, reasons for the lack of offer were identified, but in 32%, no explanation was provided.
CONCLUSION: Even in optimal circumstances, few patients were offered a trial, often because their cancer had not progressed. Findings support professional recommendations to broaden trial inclusion criteria. Findings suggest accrual rates should reflect the proportion of eligible patients who enroll.

Entities:  

Mesh:

Year:  2019        PMID: 31790330      PMCID: PMC7587411          DOI: 10.1200/JOP.19.00444

Source DB:  PubMed          Journal:  JCO Oncol Pract        ISSN: 2688-1527


  27 in total

1.  Cancer statistics, 2018.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-01-04       Impact factor: 508.702

2.  Three approaches to qualitative content analysis.

Authors:  Hsiu-Fang Hsieh; Sarah E Shannon
Journal:  Qual Health Res       Date:  2005-11

Review 3.  Barriers to recruiting underrepresented populations to cancer clinical trials: a systematic review.

Authors:  Jean G Ford; Mollie W Howerton; Gabriel Y Lai; Tiffany L Gary; Shari Bolen; M Chris Gibbons; Jon Tilburt; Charles Baffi; Teerath Peter Tanpitukpongse; Renee F Wilson; Neil R Powe; Eric B Bass
Journal:  Cancer       Date:  2008-01-15       Impact factor: 6.860

4.  Attitudes Toward Genomic Testing and Prostate Cancer Research Among Black Men.

Authors:  Charles R Rogers; Michael J Rovito; Musse Hussein; Ogechi Jessica Obidike; Rebekah Pratt; Mark Alexander; Jerica M Berge; Marc Dall'Era; Jeffrey W Nix; Christopher Warlick
Journal:  Am J Prev Med       Date:  2018-11       Impact factor: 5.043

Review 5.  Increasing Diversity in Clinical Trials: Overcoming Critical Barriers.

Authors:  Luther T Clark; Laurence Watkins; Ileana L Piña; Mary Elmer; Ola Akinboboye; Millicent Gorham; Brenda Jamerson; Cassandra McCullough; Christine Pierre; Adam B Polis; Gary Puckrein; Jeanne M Regnante
Journal:  Curr Probl Cardiol       Date:  2018-11-09       Impact factor: 5.200

6.  Influence of clinical communication on patients' decision making on participation in clinical trials.

Authors:  Terrance L Albrecht; Susan S Eggly; Marci E J Gleason; Felicity W K Harper; Tanina S Foster; Amy M Peterson; Heather Orom; Louis A Penner; John C Ruckdeschel
Journal:  J Clin Oncol       Date:  2008-06-01       Impact factor: 44.544

7.  Re-Evaluating Eligibility Criteria for Oncology Clinical Trials: Analysis of Investigational New Drug Applications in 2015.

Authors:  Susan Jin; Richard Pazdur; Rajeshwari Sridhara
Journal:  J Clin Oncol       Date:  2017-10-02       Impact factor: 44.544

Review 8.  State-of-the-science of patient navigation as a strategy for enhancing minority clinical trial accrual.

Authors:  Rahel G Ghebre; Lovell A Jones; Jennifer A Wenzel; Michelle Y Martin; Raegan W Durant; Jean G Ford
Journal:  Cancer       Date:  2014-04-01       Impact factor: 6.860

Review 9.  Are racial and ethnic minorities less willing to participate in health research?

Authors:  David Wendler; Raynard Kington; Jennifer Madans; Gretchen Van Wye; Heidi Christ-Schmidt; Laura A Pratt; Otis W Brawley; Cary P Gross; Ezekiel Emanuel
Journal:  PLoS Med       Date:  2005-12-06       Impact factor: 11.069

10.  Systematic Review and Meta-Analysis of the Magnitude of Structural, Clinical, and Physician and Patient Barriers to Cancer Clinical Trial Participation.

Authors:  Joseph M Unger; Riha Vaidya; Dawn L Hershman; Lori M Minasian; Mark E Fleury
Journal:  J Natl Cancer Inst       Date:  2019-03-01       Impact factor: 13.506

View more
  3 in total

1.  Feasibility of Randomized Controlled Trials for Cancer Drugs Approved by the Food and Drug Administration Based on Single-Arm Studies.

Authors:  Rebekah Rittberg; Piotr Czaykowski; Saroj Niraula
Journal:  JNCI Cancer Spectr       Date:  2021-06-30

2.  Decision-making about clinical trial options among older patients with metastatic cancer who have exhausted standard therapies.

Authors:  Mazie Tsang; Rebecca J DeBoer; Sarah B Garrett; Daniel Dohan
Journal:  J Geriatr Oncol       Date:  2022-02-04       Impact factor: 3.929

Review 3.  A Review of Research on Disparities in the Care of Black and White Patients With Cancer in Detroit.

Authors:  Michael S Simon; Sreejata Raychaudhuri; Lauren M Hamel; Louis A Penner; Kendra L Schwartz; Felicity W K Harper; Hayley S Thompson; Jason C Booza; Michele Cote; Ann G Schwartz; Susan Eggly
Journal:  Front Oncol       Date:  2021-07-07       Impact factor: 6.244

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.